Free Trial

Context Therapeutics (CNTX) Competitors

Context Therapeutics logo
$0.84 +0.01 (+1.30%)
Closing price 04:00 PM Eastern
Extended Trading
$0.87 +0.03 (+3.95%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CNTX vs. PRQR, INZY, TRDA, ACB, IMMP, NBTX, FENC, TKNO, EDIT, and SCPH

Should you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include ProQR Therapeutics (PRQR), Inozyme Pharma (INZY), Entrada Therapeutics (TRDA), Aurora Cannabis (ACB), Prima BioMed (IMMP), Nanobiotix (NBTX), Adherex Technologies (FENC), Alpha Teknova (TKNO), Editas Medicine (EDIT), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry.

Context Therapeutics vs. Its Competitors

Context Therapeutics (NASDAQ:CNTX) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

In the previous week, Context Therapeutics had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 2 mentions for Context Therapeutics and 1 mentions for ProQR Therapeutics. Context Therapeutics' average media sentiment score of 1.66 beat ProQR Therapeutics' score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Context Therapeutics Very Positive
ProQR Therapeutics Neutral

Context Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 554.14%. ProQR Therapeutics has a consensus target price of $8.00, indicating a potential upside of 253.98%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than ProQR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Context Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17
ProQR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

Context Therapeutics has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Context TherapeuticsN/AN/A-$26.73M-$0.31-2.71
ProQR Therapeutics$20.46M11.62-$30.04M-$0.35-6.46

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 2.8% of Context Therapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Context Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -157.04%. Context Therapeutics' return on equity of -29.78% beat ProQR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Context TherapeuticsN/A -29.78% -29.08%
ProQR Therapeutics -157.04%-53.49%-22.07%

Context Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.

Summary

Context Therapeutics beats ProQR Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Context Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNTX vs. The Competition

MetricContext TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$74.45M$2.52B$5.70B$9.48B
Dividend YieldN/A1.76%4.59%3.99%
P/E Ratio-2.719.1227.9019.95
Price / SalesN/A746.51442.19102.72
Price / CashN/A166.2336.5558.97
Price / Book0.665.228.635.90
Net Income-$26.73M$30.99M$3.24B$258.42M
7 Day Performance-7.80%4.29%3.22%1.94%
1 Month Performance46.02%13.40%10.72%12.02%
1 Year Performance-62.46%0.59%34.94%20.81%

Context Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNTX
Context Therapeutics
3.3459 of 5 stars
$0.84
+1.3%
$5.50
+554.1%
-62.6%$74.45MN/A-2.717Positive News
PRQR
ProQR Therapeutics
2.1699 of 5 stars
$2.48
+6.9%
$8.00
+222.6%
+15.1%$260.92M$20.46M-7.09180
INZY
Inozyme Pharma
2.8896 of 5 stars
$4.00
flat
$11.75
+193.8%
N/A$258.25MN/A-2.3750
TRDA
Entrada Therapeutics
2.9029 of 5 stars
$6.80
+3.8%
$25.67
+277.5%
-62.8%$258.08M$172.22M8.40110
ACB
Aurora Cannabis
0.4267 of 5 stars
$4.58
+2.0%
N/A-20.4%$257.44M$246.72M41.641,130
IMMP
Prima BioMed
1.0632 of 5 stars
$1.69
+2.4%
$7.00
+314.2%
-17.6%$246.81M$5.14M0.002,021Positive News
Upcoming Earnings
NBTX
Nanobiotix
1.2177 of 5 stars
$5.15
-0.4%
$8.00
+55.3%
+8.9%$242.72M$39.18M0.00100Gap Up
FENC
Adherex Technologies
2.5136 of 5 stars
$8.79
+0.1%
$13.00
+47.9%
+30.3%$242.60M$47.54M-17.2410
TKNO
Alpha Teknova
2.2779 of 5 stars
$4.49
-6.7%
$12.00
+167.3%
+103.2%$239.95M$38.25M-9.35240News Coverage
Analyst Upgrade
EDIT
Editas Medicine
4.0444 of 5 stars
$2.85
-1.0%
$4.70
+64.9%
-38.3%$238.57M$32.31M-0.94230
SCPH
scPharmaceuticals
4.3774 of 5 stars
$4.48
+2.3%
$14.00
+212.5%
+9.1%$236.50M$36.33M-2.3530Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:CNTX) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners